文献速递关节外科

大直径金属对金属全髋关节置换术平均7.1年翻修率高:一项登记研究

High Revision Rate for Large-head Metal-on-metal THA at a Mean of 7.1 Years: A Registry Study.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

基于芬兰关节置换登记系统,比较2004至2013年间6种大直径股骨头金属对金属全髋关节置换术(MoM THA)共10959例与常规THA对照5177例的10年竞争风险生存率,匹配5166对。结果显示MoM THA 10年无翻修生存率83%低于常规THA的92%,翻修率不可接受,支持放弃使用并建议定期随访。

要点

  • 大直径头MoM THA的10年无全因翻修生存率为83%(95%CI 82%-84%),低于常规THA的92%(95%CI 91%-93%)。
  • 从术后第4年起,每种大直径头MoM THA翻修风险均高于常规THA对照组。
  • MoM THA最常见翻修原因为金属碎屑不良反应,而常规THA对照组以脱位为主。

核心结论

  • 芬兰关节置换登记系统中该时间段所有大直径头MoM THA的翻修率高得不可接受,作者认为这支持放弃其使用的决定。
  • 与其他国家组织的指令一致,作者推荐对所有大直径头MoM THA患者进行定期随访。
  • 作者认为应基于本研究结果,在植入物整个寿命期内维持严格的随访指南,以评估患者症状并在有指征时建议翻修。

研究设计与样本

  • 基于芬兰关节置换登记系统的登记研究,纳入2004至2013年间芬兰最常用的6种大直径头(≥38 mm)MoM THA假体共10959例植入物。
  • 常规THA对照组由2002至2013年间最常用的两种假体(Vision/Bimetric和ABG II/ABG II)组成,摩擦界面为金属对聚乙烯或陶瓷对陶瓷,共5177例。
  • 按年龄组(<49、50-54、55-59、60-64、65-69、70-74和75+岁)、性别、诊断(骨关节炎、其他)和医院年手术量(<100例/年、≥100例/年)匹配,识别出5166对匹配对。
  • 芬兰登记系统初次THA完整性>95%,患者从死亡日期或移居时点删失,随访持续至2015年底。
  • 以任何原因翻修作为随访失败终点,采用校正患者死亡为竞争事件的累积发生率函数计算植入物生存率(未翻修比例),并用Cox回归模型估计大直径头MoM植入物组的翻修风险比(HR)及95%CI,校正年龄组、性别、诊断和医院年手术量。

主要发现

  • 大直径股骨头THA的10年无全因翻修生存率为83%(95%CI 82%-84%),低于常规THA对照组的92%(95%CI 91%-93%)。
  • 在植入物层面,从术后第4年起,每种大直径头MoM THA与常规THA对照组相比翻修风险均更高。
  • MoM THA中生存率最高为ReCap/Bimetric的88%(95%CI 86%-90%),最低为召回的ASR配合Summit®或Corail®柄的46%(95%CI 41%-51%)。
  • MoM THA组最常见翻修原因为金属碎屑不良反应,而常规THA对照组以脱位为主。

临床怎么用

  • 作者推荐对所有大直径头MoM THA患者进行定期随访,与其他国家组织的指令一致。
  • 作者认为应基于本研究结果,在植入物整个寿命期内维持严格的随访指南,以评估患者症状并在有指征时建议翻修。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Large-diameter head metal-on-metal (MoM) THA has largely been abandoned as a result of higher than anticipated revision rates. However, the majority of these implants are still in situ. Although earlier reports from the Finnish Arthroplasty Register noted similar short-term survivorship between large-diameter head MoM THA and conventional cemented THA, longer term survivorship of this population is unclear. Although reported revision rates for this implant group have been high, the majority of these implants have not been revised and followup is important to improve long-term management. QUESTIONS/PURPOSES: The purposes of this study were (1) to compare the 10-year competing risk survivorship of large-diameter head MoM THA with the survivorship of conventional THA in the Finnish Arthroplasty Register; (2) to report the large-diameter head MoM THA survival at the manufacturer/brand level; and (3) to identify the most common reasons for revision of large-diameter head MoM THA in the Finnish Arthroplasty Register. METHODS: The six most commonly used large-diameter head (≥ 38 mm) MoM THA devices in Finland between years 2004 and 2013 were selected (n = 10,959 implants). The completeness of the Finnish Registry is > 95% in primary THA and patients are censored from the date of death or at the point of emigration; followup continued until the end of 2015. The conventional THA control group consisted of the two most frequently used devices (Vision/Bimetric and ABG II/ABG II) with metal-on-polyethylene or ceramic-on-ceramic bearing surfaces implanted between 2002 and 2013 (n = 5177). The study group was formed by selecting all pairs of large-diameter head MoM and reference THA protheses within the same age group ( < 49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years), sex, diagnosis (osteoarthritis, other), and hospital yearly operation count (< 100 operations yearly, ≥ 100 operations yearly); 5166 matched pairs were identified. Revision for any reason was considered as the failure endpoint of followup. Implant survival (the proportion not revised) was calculated from corresponding cumulative incidence function adjusted for patient death as a competing event for revision. Large-diameter head MoM implant group revision hazard ratios with 95% confidence intervals were estimated with age group, sex, diagnosis, and hospital yearly operation count as confounding factors in a Cox regression model. RESULTS: Ten-year survivorship free from all-cause revision was lower for THAs that used a large-diameter femoral head than it was for the control group of conventional THA (83% [95% confidence interval {CI}, 82%-84%] versus 92% [95% CI, 91%-93%]). At the implant level, every large-diameter head MoM THA had a higher risk for revision compared with the conventional THA control group from the fourth postoperative year onward. The highest survival of MoM THA was 88% (95% CI, 86%-90%) for the ReCap/Bimetric and the lowest survival was 46% (95% CI, 41%-51%) for the recalled ASR with either the Summit® or Corail® stem. The most common revision reason in the MoM THA group was adverse reaction to metal debris, whereas dislocation was predominant in the conventional THA control group. CONCLUSIONS: The revision rate for all large-diameter head MoM THAs in this timeframe in the Finnish Arthroplasty Register is unacceptably high and in our view supports the decision to abandon their use. In agreement with the directives of other national organizations, we recommend regular followup of all patients with large-diameter head MoM THA. Based on our results, strict guidelines for followup should be maintained over the lifetime of the implant to assess patient symptoms and recommend revision when indicated. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Seppänen M, Laaksonen I, Pulkkinen P, et al. High Revision Rate for Large-head Metal-on-metal THA at a Mean of 7.1 Years: A Registry Study. Clin Orthop Relat Res. 2018. PMID: 29480891. doi:10.1007/s11999.0000000000000159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。